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Abstract: The effect of an acyclic synthetic retinoid analogue NIK-333, on 
the restoration of liver mass and recovery of liver function after 70% partial 
hepatectomy, was compared with natural retinoids in rats in vivo. NIK-333 
(0.4 mg/kg/day, p.o.)- and all-trans-retinoic acid (ATRA: 4 mg/kg/day, 
p.o.)-treated rats showed an approx. 1.3- and 1.2-fold increase in 
liver-to-body weight ratio, respectively, compared to solvent-administered 
control rats on day 3 after 70% partial hepatectomy. Accordingly, 
5-bromo-2’-deoxyuridine (BrdU)-labeling index in the regenerating liver 
was significantly higher in NIK-333- and ATRA-treated rats compared with 
control rats on days 0.5 and 1. However, retinol (40 mg/kg/day, p.o.) did not 
significantly increase either the liver-to-body weight ratio or the BrdU 
labeling index. In control rats, liver-related serum transaminase activities 
such as alanine aminotransferase and aspartate aminotransferase, were 
rapidly elevated on day 1 and then decreased to near pre-operative levels on 
day 5 following 70% partial hepatectomy. NIK-333 significantly lowered 
serum transaminases on days 1 and 3 after 70% partial hepatectomy 
compared with solvent-administered control rats. The 
transaminase-lowering effect of NIK-333 was more effective than that of 
ATRA. Retinol did not significantly decrease serum transaminases 
compared with the control. These results demonstrate that of the three 
retinoids, NIK-333 was the most potent in promoting the regeneration of 
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liver mass and function with full recovery after 70% partial hepatectomy.  
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1. Introduction  
Vitamin A and its natural and synthetic derivatives are known as 
retinoids (Murphy et al., 2007). Vitamin A alcohol is the physiological form 
of vitamin A. Retinoic acid is a natural product derived from the metabolism 
of retinol. Retinoic acid is also known as tretinoin or all-trans-retinoic acid 
(ATRA). ATRA is the main signaling retinoid in the body and is vital for 
biological functions such as embryogenesis, growth, and differentiation, as 
well as for vision and reproduction (Dragnev et al., 2000). In addition, 
retinoids have been shown to exert an anticarcinogenic effect through the 
suppression of cell cycle, and the induction of apoptosis and/or 
differentiation (de Almeida Vasconcelos Fonseca et al., 2005; Kagawa et al., 
2004; Nakamura et al., 1996; Suzuki et al., 2002). 
Acyclic retinoid (NIK-333), a novel synthetic vitamin A analogue, has a 
slightly different chemical structure from natural retinoic acid (Araki et al., 
1995; Nakamura et al., 1995). Acyclic retinoids are considered to act in a 
similar way to natural retinoic acid, because they bind to cellular retinoic 
acid-binding protein with strong binding affinity (Araki et al., 1995; 
Chambon, 1996; Garttini et al., 2007).  A number of retinoids have been 
assessed with the aim of determining their role in chemoprophylaxis of 
chemical carcinogens. It has been reported that NIK-333 retains 
chemopreventive activity and is less toxic than ATRA (Muto et al., 1996).  
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Both natural and synthetic retinoids have been used for the treatment of 
patients with breast carcinomas, head and neck squamous cell carcinomas, 
and acute leukemia (Hansen et al., 2000).  
However, in spite of the proposed therapeutic effects of ATRA and NIK-333, 
very little data is available on its effects on normal (non-tumorous) liver cell 
proliferation. In contrast to malignant cell lines, it has been reported that 
normal parenchymal hepatocytes significantly proliferate during ATRA 
treatment. For instance, Ledda-Columbano et al. showed that ATRA 
administration in the diet increased DNA synthesis in mouse liver, at 1 and 
2 weeks. Furthermore, increase in mitotic index paralleled that of 
bromodeoxyuridine incorporation (Ledda-Columbano et al., 2004; Ohtake et 
al., 2006). In rat liver, however, retinoic acid has been shown to inhibit 
regeneration after partial hepatectomy, most probably through repression 
of the expression of c-fos and c-jun (Ozeki and Tsukamoto, 1999). ATRA is 
reported to be a potent inhibitor of DNA synthesis in the primary cultures of 
hepatocytes from mature rats (Ikeda and Fujiwara, 1993). Hence, the 
regulation of hepatocyte proliferation by natural and synthetic retinoids is 
far more complex than initially thought and is often controversial. It 
remains to be clarified the effects that retinoids have on liver regeneration 
and the mechanisms involved.  
The purpose of this study was to evaluate the effects of NIK-333 on the 
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restoration of liver mass and recovery of liver function, compared with the 
effects of natural retinoids (ATRA and retinol), in 70% partially 
hepatectomized rats in vivo. In order to examine whether retinoids would 
protect the integrity of the liver after 70% partial hepatectomy, we 
measured the activities of liver-related cytosolic enzymes such as alanine 
aminotransferase (ALT) and aspartate aminotransferase (AST), in sera.  
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2. Materials and Methods 
2.1. Animals 
Seven-week-old male Wistar rats weighing 200 g were obtained from 
Tokyo Experimental Animal Co. (Tokyo, Japan). The rats were housed in a 
controlled temperature of 24 C under a 12 h light-dark cycle, and were fed 
standard laboratory chow and water ad libitum. The rats were handled 
humanely in accordance with the Guidelines for the Care and Use of 
Laboratory Animals of Josai University. 
 
2.2. 70% partial hepatectomy and drug administration 
 70% (two-thirds) partial hepatectomy was performed under ether 
anesthesia according to the method of Higgins and Anderson (Higgins and 
Anderson, 1931), with minor modifications. In brief, the left lateral and 
median hepatic lobes, constituting approximately 70% of the total liver 
weight, were ligated and resected. In sham-operated controls that were 
similarly anesthetized, the livers were briefly removed from the peritoneal 
cavity, but not tied or excised. 
 The rats were randomly divided into 4 groups that received either a 
solvent (soybean oil), NIK-333, all-trans retinoic acid, or retinol. NIK-333 
and natural retinoids were emulsified in soybean oil. Each group was 
treated with oral administration of either a solvent (control: soybean oil, 4 
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mL/kg), NIK-333 (0.4 mg/kg), all-trans retinoic acid (4.0 mg/kg), or retinol 
(40 mg/kg), once per day (at 10 A.M.). The administration was repeated and 
continued for 1 to 14 days unless otherwise indicated. 
 
2.3. Determination of liver regeneration 
 All rats were killed at indicated time points after 70% partial 
hepatectomy under ether anesthesia. The regenerating liver was excised, 
and moist liver weight after regeneration and body weight was measured. 
The ratio of total liver weight after regeneration was normalized to body 
weight and used as an indicator of liver regeneration (Assy and Minuk, 
1997). 
 
2.4. 5-Bromo-2’-deoxyuridine (BrdU) incorporation 
Liver regeneration monitored by mitotic index demonstrates nuclear 
5-bromo-2’-deoxyuridine (BrdU) incorporation into hepatocyte DNA after 
70% partial hepatectomy, according to a method previously described 
(Gratzner, 1982; Ishiki et al., 1992). BrdU, a thymidine analogue, is 
incorporated into hepatocyte nuclei during DNA synthesis (S phase in cell 
cycle). BrdU incorporation is a useful indicator of the effect of growth factors 
on cell proliferation in a variety of experimental systems. BrdU (50 mg/kg, 
i.p.) was injected into rats and 2 h later the rats were anesthetized with 
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ether and the livers removed. In brief, livers were fixed in 10% neutralized 
formalin and embedded in paraffin. Paraffin-embedded tissue sections (5 
m thick) were deparaffinized and stained with Hematoxylin. For assaying 
the labeling index, deparaffinized liver sections were incubated in 2N HCl 
for 30 min, washed several times with phosphate-buffered saline (pH7.4), 
and stained with anti-BrdU monoclonal antibody. BrdU was detected using 
avidin DH-biotinylated horseradish peroxidase complex according to the 
manufacturer’s instructions (Exalpha, Biologicals, Inc., Maynard, USA). To 
determine the labeling index, the number of labeled nuclei out of 1000 
nuclei, in a randomly selected field were counted under a light microscope.  
To detect any histological changes on day 3 after 70% partial hepatectomy, 
sections of the regenerating liver were stained with Hematoxylin and Eosin. 
 
2.5. Determination of serum transaminase activity 
To establish whether retinoids could affect the integrity of the livers of 70% 
partially hepatectomized rats, we measured the activities of liver-related 
cytosolic enzymes in sera. After the remnant livers were removed, blood 
samples were quickly collected from the inferior vena cava. Enzyme assays 
were performed in normal rats with either NIK-333 (0.4 mg/kg), all-trans 
retinoic acid (4.0 mg/kg), retinol (40 mg/kg), or solvent (0.4 mL/kg) 
administration. Serum alanine aminotransferase (ALT) and aspartate 
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aminotransferase (AST) activities were assayed using a commercially 
available diagnostic kit according to the manufacturer’s instructions (Wako 
Pure Chemical Industries, LTD., Osaka, Japan). The enzyme reaction was 
achieved by adding the substrate with diaminobenzidine. One unit of 
enzyme activity was measured as the change in optical density of 
0.001/min/ml of serum. 
 
2.6. Materials 
  The acyclic retinoid, NIK-333 [(2E,4E,6E,10E)- 
3,7,11,15-tetramethyl-2,4,6,10,14-hexadecapentaenoic acid] was provided 
by Tokyo New Drug Research Laboratories, Pharmaceutical Division, Kowa 
Co. (Higashimurayama, Tokyo, Japan). NIK-333 was emulsified in soybean 
oil. The following reagents were obtained from Sigma Chemical Co. (St. 
Louis, MO, USA): all-trans retinoic acid (ATRA), retinol, and 
5-bromo-2’-deoxyuridine (BrdU). BrdU was dissolved in 50% 
dimethylsulfoxide at 120 mg/ml (stock solution). Monoclonal anti-BrdU 
antibody was purchased from Exalpha Biologicals, Inc. (BrdU 
Immunohistochemistry Assay Kit, Maynard MA, USA), and monoclonal 
anti-transforming growth factor-1 antibody was obtained from R & D 
Systems, Inc. (Minneapolis, MN, USA). The assay kits for serum alanine 
aminotransferase (ALT) and aspartate aminotransferase (AST) were 
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obtained from Wako Pure Chemical Industries, LTD, Osaka, Japan. All 
other reagents were of analytical grade. 
 
2.7. Statistical analysis 
 Results are presented as the mean  S.E.M. Group comparisons were 
performed by ANOVA for unpaired data followed by post hoc analysis using 
Dunnett’s multiple comparison test. P<0.05 was considered to be 
statistically significant. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 11 
3. Results 
3.1. Time course-associated effects of NIK-333 and natural retinoids on liver 
regeneration 
To examine the effect of NIK-333 on the regeneration of remnant liver 
after 70% partial hepatectomy, NIK-333 (0.4 mg/kg/day) was administered 
orally into rats and compared with the effects of all-trans-retinoic acid 
(ATRA : 4.0 mg/kg/day) and retinol (40 mg/kg/day). The ratio of total liver 
weight after regeneration normalized to body weight was used as an 
indicator of liver regeneration (Assay and Mink, 1997). After 70% partial 
hepatectomy, the liver-to-body weight ratio increased rapidly and reached 
an initial peak on day 5 in solvent-administered control rats, whereas the 
ratio increased by day 3 in NIK-333-treated rats (Fig. 1). The 
NIK-333-treated rats showed an approx. 1.3-fold increase over the 
solvent-administered controls on day 3 after 70% partial hepatectomy. This 
was statistically significant. The liver-to-body weight ratio peaked for a 
second time on day 10 after 70% partial hepatectomy and the moist liver 
weight was almost restored to pre-operative levels. Body weight did not 
differ significantly between the NIK-333-administered group and the 
solvent-administered controls from days 1 to 14. ATRA-treated rats (4.0 
mg/kg, p.o.) reached a peak on day 7, and the time course that was 
associated with the effects of ATRA was similar to that of NIK-333, as 
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assessed by the liver-to-body weight ratio (Fig. 1). There were no significant 
differences in ratios calculated from the weight of remnant livers to body 
weight in rats given retinol (40 mg/kg, p.o.) once per day after 70% partial 
hepatectomy from days 1 to 14 when compared with solvent-administered 
controls (Fig.1).  
 
3.2. Dose-dependent effects of NIK-333 and natural retinoids on liver 
regeneration 
As the recovery of liver mass following 70% partial hepatectomy peaked 3 
days after NIK-333-treatment, we decided to examine the dose-response 
effect of NIK-333 on the liver-to-body weight ratio at 3 days after the 
hepatectomy, and to compare it with that of all-trans-retinoic acid (ATRA) 
and retinol. As shown in Fig. 2, a bell-shaped dose-response curve indicates 
that a small dose of NIK-333 (0.4 mg/kg) stimulates liver regeneration, and 
that higher doses (4.0 and 40 mg/kg) are less effective. The maximal effect 
induced by NIK-333 was achieved with 0.4 mg/kg. Co-administration of 
monoclonal antibody to transforming growth factor-1 (10 g/kg/day, i.p.) 
with NIK-333 restored the typical dose-response relationship. A smaller 
dose of monoclonal antibody to transforming growth factor-1 (5 g/kg/day, 
i.p.) also restored the suppression induced by higher doses of NIK-333 
(approx. 40%; data not shown). On the other hand, ATRA showed a typical 
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dose-response curve with a maximal dose of 4.0 mg/kg. Therefore, we used 
maximal effective doses of NIK-333 (0.4 mg/kg) and ATRA (4.0 mg/kg) in 
the following experiment. Retinol (0.01~40 mg/kg) did not significantly 
increase the liver-to-body weight ratio at any of the doses tested. 
 
3.3. Light micrographs of typical liver sections from normal rats treated with 
or without NIK-333 or ATRA on day 3 after 70% partial hepatectomy.  
As shown in Fig. 1, stimulation of liver regeneration by NIK-333 and 
ATRA was most evident on day 3 after 70% partial hepatectomy, according 
to our histological studies. Sections of regenerative livers were stained with 
Hematoxylin and Eosin to aid with the observation of histological changes 
on day 3 after 70% partial hepatectomy (Fig. 3). Histology shows that there 
are almost no morphological abnormalities such as cell-swelling, atypical 
changes of tissue, or infiltration of cells in sections of remnant regenerating 
livers treated with soybean oil (B), NIK-333 (C), or ATRA (D), compared 
with sham operated controls (A). We also examined whether histological 
changes would be present already on day 1 after 70% partial hepatectomy. 
We found no histological abnormalities in the sections of retinoid-treated 
livers compared with the sham-operated controls (data not shown). 
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3.4 Distribution of hepatocytes undergoing DNA synthesis on day 1 after 
70% partial hepatectomy.  
 In Fig. 4, light micrographs reveal the typical distribution of hepatocytes 
undergoing DNA synthesis in the remnant liver of rats after sham 
operation (A), solvent (B), NIK-333 (C), or ATRA (D) treatment on day 1 
after 70% partial hepatectomy. Hepatocytes were pulsed with 
5-bromo-2’-deoxyuridine (BrdU) for 2 h in vivo and visualized by 
immunochemical staining, whereby dark spots indicate the hepatocytes 
that are undergoing DNA synthesis. Results show that NIK-333 and ATRA, 
but not sham-operated mice, significantly stimulate hepatocyte DNA 
synthesis. The BrdU labeling index of NIK-333-treated rats is significantly 
greater than that of ATRA-treated rats on day 1 after 70% partial 
hepatectomy. Hepatocytes undergoing DNA synthesis in both NIK-333- and 
ATRA-treated animals are randomly distributed within hepatic lobes. 
 
3.5. Time course-associated effects of NIK-333 and ATRA on 
5-bromo-2’-deoxyuridine (BrdU) labeling indexes on days 0 to 5 after 70% 
partial hepatectomy  
The time course-associated effects of NIK-333 and ATRA on the BrdU 
labeling index in hepatic parenchymal cells is shown in Fig. 5. Even though 
the BrdU labeling index of sham-operated rat liver sections before 70% 
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partial hepatectomy was less than 0.1%, it moderately increased from the 
first day after the procedure in solvent-treated controls. Thereafter, it 
decreased to pre-operative levels at day 4 after 70% partial hepatectomy. In 
contrast, rats administered with 0.4 mg/kg/day NIK-333 showed a 
significant increase in BrdU labeling from 1 to 15% on day 1, which then 
declined to 5% on day 2. In both groups, the BrdU-labeling indexes returned 
to pre-operative levels on days 3, 4, and 5 after subjection to 70% partial 
hepatectomy. These results indicate that NIK-333 and ATRA significantly 
extended the mitogenic activity of hepatocytes in livers after 70% partial 
hepatectomy when compared with the control group. The effects from 
retinol were not statistically significant compared with solvent-treated 
controls (data not shown). 
 
3.6. Time course-associated effects of NIK-333 and natural retinoids on 
serum transaminase activities 
Of the known liver-related enzymes, transaminases (ALT and AST) in 
serum are good markers of liver injury or damage. To examine whether or 
not NIK-333, as well as natural retinoids, could affect liver integrity after 
partial hepatectomy, we measured ALT and AST activities in sera. As 
shown in Fig. 6, serum levels of ALT rapidly increased and peaked on day 1 
in solvent-administered control rats after subjection to 70% partial 
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hepatectomy. ALT activity rapidly returned to pre-hepatectomy levels in 
solvent-treated control animals on day 3, and this continued for a further 11 
days. However, NIK-333 (0.4 mg/kg/day, p.o.) inhibited the elevation of 
serum ALT activity induced by 70% partial hepatectomy already on day 1. 
The transaminase-lowering effect of NIK-333 was significant compared 
with solvent-treated control groups on days 1 and 3 after 70% partial 
hepatectomy. On the other hand, ATRA (4.0 mg/kg/day, p.o.) and retinol (40 
mg/kg/day, p.o.) did not reduce serum ALT activity compared with the 
solvent-treated controls (Fig. 6).  
Transaminase AST also increased significantly on day 1, after 70% partial 
hepatectomy in both control- and NIK-333-treated rats (Fig. 6). 
Administration of 0.4 mg//kg NIK-333, but not 4 mg/kg ATRA or 40 mg/kg 
retinol, also suppressed the elevated AST levels compared with the controls 
on day 1 after 70% partial hepatectomy.  
 
3.7. Dose-dependent effect of NIK-333 and natural retinoids on serum 
transaminase activities 
We next examined dose-response effects of NIK-333 and natural retinoids 
on liver-specific transaminase ALT and AST activities in serum on day 1 
following 70% partial hepatectomy. As shown in Fig. 7, NIK-333 
dose-dependently lowered both ALT and AST activities with a maximal 
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effect at 0.4 mg/kg/day. ATRA and retinol did not significantly affect either 
serum ALT or AST activities in 70% partially hepatectomized rats 
compared to solvent-treated controls. 
 
 
4. Discussion  
We evaluated whether or not exogenous administration of a novel 
synthetic analog of retinoid, NIK-333, or natural retinoids could stimulate 
liver regeneration in 70% partially hepatectomized rats in vivo. We found 
that restoration was almost complete by the 12th day in 
solvent-administered control rats, based on their liver-to-body weight ratio. 
In this study, administration of NIK-333 (0.4 mg/kg, p.o.) or ATRA (4.0 
mg/kg, p.o.) significantly accelerated remnant liver regeneration, whereas 
this was not achieved with a higher dose of retinol (40 mg/kg, p.o.) compared 
to solvent-administered controls at selected time points (Fig. 1). 
Furthermore, ATRA dose-dependently stimulated liver regeneration (Fig. 2). 
In contrast, although low dose NIK-333 stimulated liver regeneration, 
higher doses of NIK-333 actually reduced liver regeneration on day 3 after 
70% partial hepatectomy compared to its maximal effect. Yet, 
co-administration of NIK-333 at higher doses with monoclonal anti-TGF-1 
antibody significantly accelerated liver regeneration. Since TGF-1 is 
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known to be a potent growth inhibitory factor in the liver (Kimura and 
Ogihara, 1999; Michalopoulos and DeFrances, 1997; Nishikawa et al., 1998), 
these results suggest that higher doses of NIK-333 stimulates endogenous 
secretion of TGF-1 from non-parenchymal hepatocytes, thus inhibiting 
liver regeneration. In Fig. 2 we also show that among the retinoids tested 
here, NIK-333 is the most potent agent in enhancing liver regeneration in 
70% partially hepatectomized rats. 
Liver regeneration was also monitored by mitotic index, which 
demonstrates nuclear 2-bromo-5’-deoxyuridine (BrdU) incorporation into 
hepatocyte DNA after 70% partial hepatectomy, according to a previously 
established method (Gratzner, 1982; Ishiki et al., 1992). When looking at 
BrdU, administration of NIK-333 (0.4 mg/kg, p.o.) or ATRA (4.0 mg/kg, p.o.) 
significantly stimulated the BrdU labeling index at days 0.5 and 1 
post-hepatectomy compared to solvent-treated controls, whereas treatment 
with retinol (40 mg/kg, p.o.) only slightly stimulated the BrdU labeling 
index (Fig. 5). To our knowledge, this is the first report showing that 
NIK-333 or ATRA are able to stimulate hepatocyte DNA synthesis during 
liver regeneration in 70% partially hepatectomized rats in vivo. The 
stimulatory effect of NIK-333 was more potent than that of ATRA. These 
results are consistent with our in vitro studies where NIK-333 is more 
potent than ATRA in stimulating hepatocyte DNA synthesis and 
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proliferation in primary hepatocyte cultures from adult rats (manuscript in 
preparation). 
Acyclic retinoid binds to cytosolic retinoic acid binding protein (CRABP) 
and to the retinoic acid receptor (RAR), thereby transactivating genes 
through the retinoic acid responsive element or by binding to the retinoid X 
receptor (RXR) and transactivating genes via the retinoid X responsive 
element (Araki et al., 1995). The potent mitogenic activity of NIK-333 or 
ATRA in parenchymal hepatocytes seems to be one of the predominant 
mechanisms that act through the retinol receptor RAR and/or RXR 
(Chambon, 1996; Kastner et al., 1995). In support of this notion, Yang et al. 
showed that liver regeneration after partial hepatectomy is delayed in 
RXR- receptor knockout mice (Yang et al., 2010). However, although the 
acyclic retinoid NIK-333 shares some characteristics with natural retinoids 
in vitro and in vivo, it has been reported that NIK-333 differs in its several 
biological effects from natural retinoids such as the all-trans and 9-cis 
retinoic acids (Komi et al., 2010; Sakabe et al., 2007; Shidoji and Ogawa, 
2004; Tsurumi et al., 1993). In fact, administration of NIK-333 resulted in a 
biphasic dose-response relationship, whereas ATRA showed a typical 
dose-response relationship (Fig. 2). This prompted the authors to speculate 
that NIK-333 might mediate different mechanisms of action from the 
natural retinoids (e.g., ATRA and 9-cis retinoic acids) in stimulating normal 
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hepatocyte proliferation. This hypothesis remains to be elucidated. 
From a therapeutic point of view, liver regeneration therapy for fulminant 
hepatitis is unsatisfactory and so sufficient liver regeneration cannot be 
expected after resection. Problems with hepatic failure arise seeing as liver 
function is markedly impaired in hepatectomized patients, from hepatitis, 
and from hepatic cancer. Hence, it is important to stimulate both the 
regeneration of mass and the recovery of function in the remnant liver after 
liver damage. However, at present, safe and efficacious therapies that 
suppress liver oncogenesis and promote proliferation of hepatocytes have 
yet to be discovered. Therefore, an agent should be developed that 
specifically promotes liver regeneration and recovery of liver function, and 
which is safe to use in the treatment of fulminant liver hepatitis, hepatic 
failure, and hepatic cancer resection.  
Muto et al. demonstrated that one-year treatment with the acyclic retinoid 
NIK-333 significantly inhibited the recurrence of hepatocellular carcinoma 
by suppressing cell cycle progression and/or inducing apoptosis (Muto et al., 
1996). Also, ATRA shows antitumor activity as strong as NIK-333 but with 
the absence of apoptosis (Okuno et al., 2004). It is known, however, that 
ATRA administration induces serious adverse effects such as retinoic acid 
syndrome (i.e., pyrexia, lung infiltration, intestinal pneumonia, renal 
failure, etc.). On the other hand, NIK-333 is a drug with a high safety 
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profile that does not cause impaired liver function or other side effects seen 
with ATRA or other retinoids (Muto et al., 1996). In this study, we show 
that NIK-333 promotes liver regeneration only at low doses. In contrast, 
ATRA dose-dependently stimulates liver regeneration (Fig. 2). Therefore, 
the mitogenic effect of ATRA must be cautioned regarding its possible use 
as an antitumoral drug (McCormick et al., 1990). Taken together, NIK-333 
is a safe agent that selectively promotes proliferation of hepatocytes only at 
low doses, and suppresses liver oncogenesis at higher doses (Kagawa et al., 
2004; Sano et al., 2005). 
To evaluate the degree of liver injury after 70% partial hepatectomy in vivo, 
the activity of liver-related enzymes in serum such as alanine 
aminotransferase (ALT) and aspartate aminotransferase (AST) were 
assayed (Figs. 6 and 7). We show that serum ALT and AST activities 
increase rapidly and significantly after 70% partial hepatectomy on day 1, 
and return almost to pre-operative levels after 2 - 3 days in 
solvent-administered control rats. An explanation for this is that in 
response to damage around the ligated area of the liver, a local 
inflammatory reaction may occur, and transient increases in serum ALT 
and AST activities are thought to appear. Hepatic resection that induces an 
increase in serum ALT and AST activities was found to be significantly 
inhibited in animals treated with NIK-333, compared to the 
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solvent-administered controls, ATRA, or the retinol group (Figs. 6 and 7; 
Ledda-Columbano et al., 2004.). These results indicate that NIK-333 can 
significantly suppress the leakage of cytosolic enzymes from liver cells and 
prevent early stage liver damage caused by 70% partial hepatectomy. 
NIK-333 is likely to have an anti-inflammatory action similar to ibuprofen 
and dexamethasone (Kimura et al., 2008). 
In conclusion, we show for the first time that chemically synthesized 
acyclic retinoid, NIK-333 in low concentrations is a potent stimulator of 
normal hepatocyte proliferation and restoration of liver function after 70% 
partial hepatectomy in rats in vivo. The underlying molecular mechanisms 
by which NIK-333 stimulates liver regeneration and restores liver function 
are still unknown at present. Hence, members of our laboratory are 
currently investigating such mechanisms in primary cultures of adult rat 
hepatocytes in vitro.  
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Legends  
Fig. 1. Time course-associated effects of NIK-333 and natural retinoids on 
liver regeneration after 70% partial hepatectomy. 
Rats were treated according to the experimental schedule described in 
Materials and Methods. Control (soybean oil; 4.0 mL/kg, p.o.), NIK-333 (0.4 
mg/kg, p.o.), ATRA (4.0 mg/kg, p.o.), or retinol (40 mg/kg, p.o.), were injected 
through an oral tube once daily (at 10 A.M.), after which the remnant livers 
were removed rapidly under ether anesthesia at the time points indicated, 
and weighed. In each experimental group n = 5-6 animals. The data is 
expressed as a percentage of the liver-to-body weight ratio on day 0. 100%: 
Sham-operated rats. Values are expressed as means±S.E.M. *, P< 0.05 ; **, 
P<0.01 compared to soybean oil-treated control. 
 
Fig. 2. Dose-dependent effect of NIK-333 and natural retinoids on liver 
regeneration on day 3 after 70% partial hepatectomy. 
Rats were treated according to the experimental schedule described in 
Materials and Methods. Control (soybean oil; 4.0 mL/kg, p.o.), NIK-333 
(0.004-40 mg/kg, p.o.) with or without monoclonal antibody to TGF-1 (10 
mg/kg, i.p.), ATRA (0.004-40 mg/kg, p.o.), or retinol (0.004-40 mg/kg, p.o.), 
were injected through an oral tube once daily (at 10 A.M.), and the remnant 
livers were removed rapidly under ether anesthesia on day 3 after 70% 
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partial hepatectomy, and weighed. The ratio of total liver weight after 
regeneration normalized to body weight was used as an indicator of liver 
regeneration. The data is expressed as a percentage of the liver-to-body 
weight ratio on day 0. Rats (n=5-8) were used in each experimental group. 
Values are the means ± S.E.M. *, P< 0.05 ; **, P<0.01 compared to 
solvent-treated controls.  
 
Fig. 3. Light micrographs showing typical liver sections from normal rats 
treated with or without administration of NIK-333 or ATRA on day 3 after 
70% partial hepatectomy.  
Histological changes in the livers of rats without any treatment (sham 
operation), or with a solvent (control), NIK-333, or ATRA, on day 3 after 
70% partial hepatectomy were examined as described in Materials and 
Methods. Liver specimens were fixed in cold 10% neutralized formalin and 
embedded in paraffin. Paraffin-embedded tissue sections (5m thick) were 
deparaffinized and stained with Hematoxylin and Eosin. A: sham 
operation, B: control (soybean oil; 4.0 mL/kg/day, p.o.), C: NIK-333, 0.4 
mg/kg/day, p.o., D: ATRA, 4.0 mg/kg/day, p.o. Bar represents 50 m. 
 
Fig. 4. Distribution of hepatocytes undergoing DNA synthesis on day 1 after 
70% partial hepatectomy.  
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Light micrographs showing typical distributions of hepatocytes undergoing 
DNA synthesis in remnant livers of rats treated without any treatment 
(sham operation) or with a solvent (control), NIK-333, or ATRA, on day 1 
after 70% partial hepatectomy. The cells were pulsed with 
5-bromo-2’-deoxyuridine (BrdU) in vivo. Liver sections (5m thick) were 
stained with Hematoxylin following immunochemical staining with a 
monoclonal antibody to BrdU as described in Materials and Methods. Dark 
spots indicate hepatocytes undergoing DNA synthesis. A: Sham operation, 
B: Control (soybean oil, 4.0 mL/kg/day, p.o.), C: NIK-333, 0.4 mg/kg/day, 
p.o.), D: ATRA, 4.0 mg/kg/day, p.o. Bar represents 50 m. 
 
Fig.5. Time course-associated effects of NIK-333 and ATRA on 
5-bromo-2’-deoxyuridine (BrdU) labeling indexes, on days 0 to 5 after 70% 
partial hepatectomy.  
BrdU-mitotic indexes were determined by BrdU incorporation into DNA 
and from immunohistochemical staining using an anti-monoclonal antibody 
to BrdU on days 0-5 after partial hepatectomy, as described in the legend of 
Fig. 4. BrdU labeling index in solvent-, NIK-333-, and ATRA-treated rats 
indicates the percentage of BrdU-positive hepatocyte nuclei out of 1000 
nuclei in a randomly selected field under a light microscope. Values are the 
means ± S.E.M. of five different rats. *, P< 0.05; **, P<0.01 compared to 
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solvent-treated control. 
 
Fig. 6. Time course-associated effects of NIK-333 and natural retinoids on 
liver-specific cytosolic transaminase (ALT and AST) activities in serum 
after subjection to 70% partial hepatectomy.  
Time course-associated effects of NIK-333 (0.4 mg/kg/day, p.o.), ATRA (4.0 
mg/kg/day, p.o.), or retinol (40 mg/kg/day, p.o.), on serum ALT (A) and AST 
(B) activities assessed on days 0-14 after 70% partial hepatectomy, as 
described in Materials and Methods. Data from control, NIK-333-, ATRA-, 
and retinol-treated rats are shown as the mean ± S.E.M. (n=5~6). *, P< 
0.05; **, P<0.01 compared to solvent-treated control. 
 
Fig. 7. Dose-dependent effect of NIK-333 and natural retinoids on 
liver-related cytosolic transaminase (ALT and AST) activities in serum on 
day 3 after subjection to 70% partial hepatectomy.  
 Rats were treated according to the experimental schedule described in 
Materials and Methods. Serum ALT and AST activities were determined as 
described in the legend of Fig. 6. Each experimental group contained 5-6 
rats. Values are represented as the means ± S.E.M. *, P< 0.05; **, P<0.01 
compared to solvent-treated controls. 
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